Loading...
•
Jun 30, 2020
Alnylam Q2 2020 Earnings Report
Alnylam reported consolidated financial results and reviewed recent business highlights
Key Takeaways
Alnylam Pharmaceuticals reported strong Q2 2020 financial results, driven by the commercial performance of ONPATTRO and GIVLAARI. The company is increasing the midpoint of its full-year revenue guidance for ONPATTRO and achieved year-over-year improvement in its non-GAAP operating loss.
Achieved Second Quarter 2020 ONPATTRO® Global Net Product Revenues of $66.5 Million, with More Than 1,050 Patients on Commercial Product Worldwide
Achieved Second Quarter 2020 GIVLAARI® Global Net Product Revenues of $11.0 Million with More Than 100 Patients on Commercial Product Worldwide
Presented Complete Results from ILLUMINATE-A Phase 3 Study of Lumasiran and Completed Filings of New Drug Application and Marketing Authorisation Application
Completed $2 Billion Strategic Financing Collaboration with Blackstone, Enabling Achievement of Self-Sustainable Financial Profile without Need for Future Equity Offerings
Alnylam
Alnylam
Alnylam Revenue by Segment
Revenue by Segment
ONPATTRO Revenue
CapyFin.comGIVLAARI Revenue
CapyFin.com Forward Guidance
Alnylam provided full year 2020 financial guidance.
Positive Outlook
- ONPATTRO net product revenues are expected to be between $280 million and $300 million.
- Net revenues from collaborations are expected to be between $100 million and $150 million.
- GAAP R&D and SG&A expenses are expected to be between $1,130 million and $1,225 million.
- Non-GAAP R&D and SG&A expenses are expected to be between $1,000 million and $1,075 million.
- The strategic financing collaboration with Blackstone under which Alnylam will receive up to $2 billion is expected to enable Alnylam’s achievement of a self-sustainable financial profile without need for future equity financings.
Revenue & Expenses
Visualization of income flow from segment revenue to net income